Optimizing Post-ACS Management and Emerging LDL-C Lowering Strategies

This episode, titled Optimizing Post-ACS Management and Emerging LDL-C Lowering Strategies, features panelists discussing the following critical questions:

How are you managing patients after a recent acute coronary syndrome?

What did the V-initiate trial evaluate in terms of LDL-C lowering therapy with inclisiran?

What were the findings and are they applicable to clinical practice?

Led by Dr. Craig Beavers, the experts examined the management of patients after a recent acute coronary syndrome, which focuses on rapid initiation of high-intensity lipid-lowering therapy, combination treatment when needed, and close follow-up to achieve aggressive LDL-C targets and reduce recurrent risk. The V-INITIATE trial evaluated the early use of inclisiran alongside standard care to determine its effectiveness in achieving timely and sustained LDL-C reduction. Findings demonstrated that inclisiran enabled a greater proportion of patients to reach guideline-recommended LDL-C levels with a simplified dosing schedule, supporting improved adherence. These results suggest strong potential for real-world application, particularly in patients who struggle to achieve targets with traditional therapies or face adherence challenges.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, Addressing Statin Intolerance and Expanding Access to Non-Statin Therapies, panelists will continue their discussion on approaches to assessing statin intolerance and the evolving roles of different providers in prescribing non-statin LDL-C–lowering therapies, including opportunities to expand involvement of primary care providers and pharmacists. It also examines best practices for monitoring and managing adverse events associated with these therapies to ensure safe, effective, and sustained lipid control.